GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » Cash Conversion Cycle

American Bio Medica (American Bio Medica) Cash Conversion Cycle : -243.42 (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is American Bio Medica Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

American Bio Medica's Days Sales Outstanding for the three months ended in Mar. 2023 was 47.57.
American Bio Medica's Days Inventory for the three months ended in Mar. 2023 was 384.26.
American Bio Medica's Days Payable for the three months ended in Mar. 2023 was 675.25.
Therefore, American Bio Medica's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2023 was -243.42.


American Bio Medica Cash Conversion Cycle Historical Data

The historical data trend for American Bio Medica's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica Cash Conversion Cycle Chart

American Bio Medica Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.94 101.45 41.53 29.47 -30.41

American Bio Medica Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.73 -106.07 -193.97 -166.89 -243.42

Competitive Comparison of American Bio Medica's Cash Conversion Cycle

For the Diagnostics & Research subindustry, American Bio Medica's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Bio Medica's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where American Bio Medica's Cash Conversion Cycle falls into.



American Bio Medica Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

American Bio Medica's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=80.96+147.65-259.02
=-30.41

American Bio Medica's Cash Conversion Cycle for the quarter that ended in Mar. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=47.57+384.26-675.25
=-243.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Bio Medica  (OTCPK:ABMC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


American Bio Medica Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of American Bio Medica's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


American Bio Medica (American Bio Medica) Business Description

Traded in Other Exchanges
N/A
Address
122 Smith Road, Kinderhook, New York, NY, USA, 12106
American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney 10 percent owner 118 PEGASUS DR., JUPITER FL 33477
Chaim Davis director 2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome director 7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous director 122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse officer: EVP, CCO, CORP SEC AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc 10 percent owner 3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin officer: Executive Vice President C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff director C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker officer: Chief Financial Officer 122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio director C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski director 300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino director 122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz director, officer: President
Richard Koskey director C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106

American Bio Medica (American Bio Medica) Headlines